PL422316A1 - Method for obtaining monoclonal antibody, the monoclonal antibody, cell CHO DG44, which co-expressions the monoclonal antibody and the composition that contains it - Google Patents
Method for obtaining monoclonal antibody, the monoclonal antibody, cell CHO DG44, which co-expressions the monoclonal antibody and the composition that contains itInfo
- Publication number
- PL422316A1 PL422316A1 PL422316A PL42231617A PL422316A1 PL 422316 A1 PL422316 A1 PL 422316A1 PL 422316 A PL422316 A PL 422316A PL 42231617 A PL42231617 A PL 42231617A PL 422316 A1 PL422316 A1 PL 422316A1
- Authority
- PL
- Poland
- Prior art keywords
- monoclonal antibody
- antibody
- cell
- cho
- obtaining
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000004186 co-expression Effects 0.000 title 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 abstract 1
- FDJKUWYYUZCUJX-AJKRCSPLSA-N N-glycoloyl-beta-neuraminic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-AJKRCSPLSA-N 0.000 abstract 1
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229960003824 ustekinumab Drugs 0.000 abstract 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Przedmiotem zgłoszenia jest sposób otrzymywania przeciwciała monoklonalnego, które jest zasadniczo identyczne z ustekinumabem, obejmujący etap hodowania komórki CHO DG44, która koekspresjonuje wymienione przeciwciało i aktywną ?2,6-sialilotransferazę. Przeciwciało uzyskane za pomocą sposobu według niniejszego zgłoszenia wykazuje brak epitopów ?-Gal oraz brak lub mniejszą ilość glikozylacji obejmujących NGNA, który dla ludzi może być immunogenny. Dodatkowo, zgłoszenie obejmuje też kompozycję farmaceutyczną zawierającą wymienione przeciwciało oraz jej zastosowania medyczne. Niniejsze zgłoszenie przedstawia także komórkę CHO DG44, która koekspresjonuje przeciwciało i aktywną ?2,6-sialilotransferazę oraz hodowlę komórkową zawierającą wymienioną komórkę CHO DG44.The subject of the application is a method for obtaining a monoclonal antibody which is substantially identical to ustekinumab, comprising the step of culturing the CHO DG44 cell which co-expresss said antibody and active α-2,6-sialyltransferase. The antibody obtained by the method of the present application shows no γ-Gal epitopes and no or less glycosylation including NGNA, which may be immunogenic to humans. In addition, the application also includes a pharmaceutical composition comprising said antibody and its medical uses. The present application also presents a CHO DG44 cell which co-expresses the antibody and active α 2,6-sialyltransferase and a cell culture containing said CHO DG44 cell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL422316A PL240405B1 (en) | 2017-07-24 | 2017-07-24 | Method for obtaining monoclonal antibody, the monoclonal antibody, cell CHO DG44, which co-expressions the monoclonal antibody and the composition that contains it |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL422316A PL240405B1 (en) | 2017-07-24 | 2017-07-24 | Method for obtaining monoclonal antibody, the monoclonal antibody, cell CHO DG44, which co-expressions the monoclonal antibody and the composition that contains it |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL422316A1 true PL422316A1 (en) | 2019-01-28 |
| PL240405B1 PL240405B1 (en) | 2022-03-28 |
Family
ID=65034002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL422316A PL240405B1 (en) | 2017-07-24 | 2017-07-24 | Method for obtaining monoclonal antibody, the monoclonal antibody, cell CHO DG44, which co-expressions the monoclonal antibody and the composition that contains it |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL240405B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112852743A (en) * | 2021-01-25 | 2021-05-28 | 江苏荃信生物医药有限公司 | Cell strain of biological similar medicine for producing Usunitumumab and production method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007135194A2 (en) * | 2006-05-24 | 2007-11-29 | Universite De Provence (Aix Marseille I) | Preparation and uses of gene sequences encoding chimerical glycosyltransferases with optimized glycosylation activity |
| WO2015003811A1 (en) * | 2013-07-11 | 2015-01-15 | Glycotrek | Methods for producing sialylated therapeutic proteins |
-
2017
- 2017-07-24 PL PL422316A patent/PL240405B1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007135194A2 (en) * | 2006-05-24 | 2007-11-29 | Universite De Provence (Aix Marseille I) | Preparation and uses of gene sequences encoding chimerical glycosyltransferases with optimized glycosylation activity |
| WO2015003811A1 (en) * | 2013-07-11 | 2015-01-15 | Glycotrek | Methods for producing sialylated therapeutic proteins |
Non-Patent Citations (1)
| Title |
|---|
| ONITSUKA M. ET AL, ENHANCEMENT OF SIALYLATION ON HUMANIZED IGG-LIKE BISPECIFIC ANTIBODY BY OVEREXPRESSION OF 1+-2,6-SIALYLTRANSFERASE DERIVED FROM CHINESE HAMSTER OVARY CELLS, 29 December 2011 (2011-12-29) * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112852743A (en) * | 2021-01-25 | 2021-05-28 | 江苏荃信生物医药有限公司 | Cell strain of biological similar medicine for producing Usunitumumab and production method |
Also Published As
| Publication number | Publication date |
|---|---|
| PL240405B1 (en) | 2022-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520420801B1 (en) | AIL anti-11 antibody | |
| CL2020001048A1 (en) | Monoclonal antibodies against bcma. (divisional request 201800281) | |
| MY193353A (en) | Anti-vegf protein compositions and methods for producing the same | |
| MY205672A (en) | Anti-phf-tau antibodies and uses thereof | |
| MA53356B1 (en) | Subcutaneous anti-cd38 antibody formulations and uses thereof | |
| MX2020007945A (en) | Stabilized rsv f proteins and uses thereof. | |
| SA523451582B1 (en) | CCR8 antibodies | |
| BR112019002848A2 (en) | anti-lag-3 antibody | |
| MX389274B (en) | ANTIBODY THAT NEUTRALIZES THE HUMAN RESPIRATORY SYNCYTIAL VIRUS. | |
| PL3980392T3 (en) | BIOMASS COMPOSITION CONTAINING INSECT PARTICLES, METHOD OF PRODUCING IT AND USE OF SAID BIOMASS COMPOSITION | |
| JOP20220204A1 (en) | Human anti-CD19 antibodies | |
| EA202092849A1 (en) | Monospecific and multispecific antibodies to TMEFF2 AND THEIR APPLICATION | |
| CL2023003155A1 (en) | Compositions of anti-tslp antibodies and uses thereof | |
| EA201990998A1 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PRODUCING THEM | |
| EA202092508A1 (en) | COMPOSITIONS BASED ON ANTIBODIES TO HUMAN PD-L1 | |
| EA201991319A1 (en) | VACCINES OF ATTENUATED SWINE INFLUENZA AND METHODS OF THEIR MANUFACTURE AND APPLICATION | |
| MX2024001304A (en) | Compositions and methods for anti-pacap antibodies. | |
| PL422316A1 (en) | Method for obtaining monoclonal antibody, the monoclonal antibody, cell CHO DG44, which co-expressions the monoclonal antibody and the composition that contains it | |
| MX2024006208A (en) | ANTI-TREM2 ANTIBODY AND ITS USES. | |
| MX2023014984A (en) | ANTI-CSP ANTIBODIES. | |
| MX2025009846A (en) | COMPOSITIONS COMPRISING NUCLEIC ACID MOLECULES ENCODING SYNTHETIC ANTI-IL-6 AND ANTI-CD126 ANTIBODIES | |
| EA201990768A1 (en) | OPTIMIZED SYNTHETIC CONSENSUS IMMUNOGENIC COMPOSITIONS AIMED AT FIBROBLAST ACTIVATION PROTEIN | |
| EA201892408A1 (en) | DEODORIZING PRODUCTS | |
| CO2021012209A2 (en) | Composition for oral care | |
| PL418557A1 (en) | 4'-O-β-D-glucopyranosyl-4,2'-dihydroxy-3'-[3"-methylbutyl]-6'-methoxy-α,β-dihydrochalcone and method for obtaining 4'-O-β-D-glucopyranosyl-4,2'-dihydroxy-3'-[3"-methylbutyl]-6'-methoxy-α,β-dihydrochalcone |